AI Stock Memo: A - Agilent - RankAlpha

A

Rating neutralAI Memo

Agilent

As of 2026-05-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 FY2026 earnings on May 27 is the next hard read on momentum • 2026-05-27

Expected move: -14%

Biggest risk

The bear case is that tariff-driven cost pressure, ongoing competitive pricing, and any slowdown in instrument demand offset the Q1 growth story, leaving the stock stuck near current levels even if headline revenue stays steady [#10-Q-2026-03-03][#10-K-2025-12-22].

Invalidation

Break below $96 or thesis failure.

What would change my mind?

Q1 company results were constructive: Agilent reported 4.4% core growth and raised FY2026 revenue and EPS guidance, which leaves room for the stock to rerate if Q2 confirms that momentum and the Biocare deal closes on time [#IR-2026-02-25][#PR-2026-03-09].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-18

Base target

$116

p=52%

Bull target

$132

p=20%

Bear target

$96

p=28%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Biocare acquisition can add pathology growth and mix if it closes on schedule
Tariff mitigation is still a fiscal-year 2026 margin variable
Q1 company results were constructive: Agilent reported 4.4% core growth and raised FY2026 revenue and EPS guidance, which leaves room for the stock to rerate if Q2 confirms that momentum and the Biocare deal closes on time [#IR-2026-02-25][#PR-2026-03-09].

BearKey bullets

Biocare still needs regulatory approvals and integration execution, and EPS accretion is not expected until roughly 12 months after close [#PR-2026-03-09].
Competitive and pricing pressure remain a standing risk in Agilent's filings, especially if demand softens or the replacement cycle cools [#10-Q-2026-03-03][#10-K-2025-12-22].
Tariff changes already hit Q1 cost of revenue, and the company says further trade-policy shifts could still affect future results even after mitigation [#10-Q-2026-03-03].

WatchKey bullets

Q2 FY2026 earnings on May 27 is the next hard read on momentum

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $116 (p=52%)

Bull/Bear spread: -3% / -29%

Vs latest close: Bull -3% · Base -14% · Bear -29%

Scenario probabilities

Bull Target: $132 (p=20%)Base Target: $116 (p=52%)Bear Target: $96 (p=28%)

Commentary

Coverage is company-led rather than analyst-led: the latest primary-source items are the May 27 earnings date, the May 4 CLO transition 8-K, the Biocare acquisition announcement, and the Q1 release that raised FY2026 guidance. That is mildly constructive, but there is no fresh revision set or social packet here, so conviction stays moderate and the stock remains a monitoring name into the next earnings print [#8-K-2026-05-04][#IR-2026-04-28].

As of 2026-05-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Biocare acquisition can add pathology growth and mix if it closes on schedule
Tariff mitigation is still a fiscal-year 2026 margin variable

Scenarios

Bull Target (Scenario probability)

$132 / p=20% prob

Base Target (Scenario probability)

$116 / p=52% prob

Bear Target (Scenario probability)

$96 / p=28% prob

Price $136 as of 2026-05-29

Nearest Scenario: Bull (∆ 3%)

Targets vs latest close: Bull -3% · Base -14% · Bear -29%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-27
Q2 FY2026 earnings on May 27 is the next hard read on momentum
Agilent said it will release second-quarter fiscal 2026 financial results after the market close on May 27, with the call the same afternoon. That makes the print the next clean check on whether Q1 core growth and raised FY26 guidance are holding up into the back half of the year.
Prob 75.00% • Move 5.50% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Biocare acquisition can add pathology growth and mix if it closes on schedule
2026-10-31
Agilent said the $950 million Biocare Medical acquisition is expected to be accretive to top-line growth, margin profile and non-instrument revenue mix in year one, with EPS accretion about 12 months after close and closing targeted no later than fiscal Q4 2026. That gives the stock a tangible longer-dated mix and growth lever if approvals and integration stay on track [#PR-2026-03-09].
Prob 65% • Move 5% • Priced-in 40%
Tariff mitigation is still a fiscal-year 2026 margin variable
2026-10-31
The 10-Q says tariff changes adversely affected cost of revenue in the January quarter, but management expects to fully offset the current impact during fiscal 2026 through supply-chain optimization, targeted pricing actions and other cost-efficiency steps. If mitigation works, margins can hold; if trade policy worsens, margin pressure can re-emerge [#10-Q-2026-03-03].
Prob 60% • Move 4% • Priced-in 50%

Risks

Biocare still needs regulatory approvals and integration execution, and EPS accretion is not expected until roughly 12 months after close [#PR-2026-03-09].
Competitive and pricing pressure remain a standing risk in Agilent's filings, especially if demand softens or the replacement cycle cools [#10-Q-2026-03-03][#10-K-2025-12-22].
Tariff changes already hit Q1 cost of revenue, and the company says further trade-policy shifts could still affect future results even after mitigation [#10-Q-2026-03-03].
The May 27 earnings release is a near-term binary checkpoint for whether raised FY26 guidance is sustainable or whether management has to reset expectations.

Peers

Symbol	Summary
WAT	Direct analytical-instruments and lab-workflow comparator; useful for chromatography, replacement-cycle, and service-attachment checks. Agilent's 10-K names Waters among principal competitors [#10-K-2025-12-22].
TMO	Large life-science tools and services benchmark; better for gauging end-market demand and mix than for pure pharma read-through. Agilent's 10-K names Thermo Fisher as a principal competitor [#10-K-2025-12-22].
DHR	Broad diagnostics and instruments benchmark, especially for pathology and service-workflow execution. Agilent's 10-K names Danaher and related divisions as competitors across relevant markets [#10-K-2025-12-22].
BRKR	Focused analytical-instruments peer that is useful for checking whether replacement-cycle demand and high-end workflow spending are broad-based or Agilent-specific. Agilent's 10-K names Bruker as a principal competitor [#10-K-2025-12-22].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-18